GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Solriamfetol - SUNOSI oral tablets

Local official-label summaryBase record retrieved 2026-09-09See the evidence for this drug2 sources available - open source summaries, references and comparisons

SUNOSI / Solriamfetol

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Keep the renal titration interval with the renal maximum

The moderate-impairment schedule uses at least seven days before an increase. This is not the general three-day titration schedule.

Before applying: Review the source-specific interval, maximum, indexed eGFR and monitoring together.

Also check: Keep the renal titration interval with the renal maximum

Official source

SUNOSI - official renal dose and monitoring check

Product / population
SUNOSI - official renal dose and monitoring check; selected renal passages, not a complete prescribing monograph.
Renal measure
eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.

Renal dosing, restrictions and evidence limits

At eGFR 30-59 mL/min/1.73 m2, begin 37.5 mg once daily; maximum 75 mg once daily after at least 7 days if appropriate. At eGFR 15-29, use 37.5 mg once daily as both starting and maximum dose. Below 15, use is not recommended. Moderate/severe impairment increases the risk of blood-pressure, heart-rate and psychiatric adverse effects because half-life is prolonged. Control hypertension before treatment and monitor blood pressure regularly; monitor psychiatric symptoms. Do not convert a longer half-life into an unlisted dialysis or alternate-day regimen.

Source revision: Prescribing information revised May 2026. | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=362f206b-73e7-4009-8c34-5a9df55679ab

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

SUNOSI - official renal dose and monitoring check

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

SUNOSI - official renal dose and monitoring check; selected renal passages, not a complete prescribing monograph.

Renal method: eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Retrieved: 2026-09-09

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - SUNOSI

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Solriamfetol - SUNOSI oral tablets; selected renal passages, not a complete prescribing monograph.

Renal method: eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Keep the renal titration interval with the renal maximum

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

scope and applicability

Keep the renal titration interval with the renal maximum

The moderate-impairment schedule uses at least seven days before an increase. This is not the general three-day titration schedule.

How to use this: Review the source-specific interval, maximum, indexed eGFR and monitoring together.

GlobalRPh RX List - SUNOSISUNOSI - official renal dose and monitoring check

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeSUNOSI - official renal dose and monitoring checkGlobalRPh RX List - SUNOSI
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/sunosi-drug/

Exact product and population

Solriamfetol - SUNOSI oral tablets; selected renal passages, not a complete prescribing monograph.

RDM53-SCOPE-solriamfetol-sunosi · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

SUNOSI - official renal dose and monitoring check

Open original reference

Open / share this exact local source

DailyMed / Axsome Therapeutics, Inc. · SUNOSI - official renal dose and monitoring check; selected renal passages, not a complete prescribing monograph.

Renal method: eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Source date: Prescribing information revised May 2026.
Retrieved: 2026-09-09

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At eGFR 30-59 mL/min/1.73 m2, begin 37.5 mg once daily; maximum 75 mg once daily after at least 7 days if appropriate. At eGFR 15-29, use 37.5 mg once daily as both starting and maximum dose. Below 15, use is not recommended. Moderate/severe impairment increases the risk of blood-pressure, heart-rate and psychiatric adverse effects because half-life is prolonged. Control hypertension before treatment and monitor blood pressure regularly; monitor psychiatric symptoms. Do not convert a longer half-life into an unlisted dialysis or alternate-day regimen.

RDM53-official-solriamfetol-sunosi-d91445b8c4-C1 · Source locator: Sections 2.5, 5.1 and 5.2; label header and PI revision.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=362f206b-73e7-4009-8c34-5a9df55679ab
Retrieved
2026-09-09
Exact label title
SUNOSI - solriamfetol tablet, film coated
DailyMed Set ID
362f206b-73e7-4009-8c34-5a9df55679ab
Labeler
Axsome Therapeutics, Inc.
DailyMed page updated
2026-05-05
Label revision
Prescribing information revised May 2026.
Renal-function method
eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Source date/version
Prescribing information revised May 2026.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
ed174ecd1e8fa6474d1418ad97b4dbf7f8b37ff101b1654196deec6c630fe39a
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - SUNOSI

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Solriamfetol - SUNOSI oral tablets; selected renal passages, not a complete prescribing monograph.

Renal method: eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For adult use, eGFR 30-59 mL/min/1.73 m2: start 37.5 mg once daily; based on response and tolerability, increase only after at least 7 days to a maximum of 75 mg once daily. At eGFR 15-29, both the starting and maximum dose are 37.5 mg once daily. Use is not recommended below 15 (ESRD). The renal titration interval is not the general three-day titration interval. These limits do not establish a dialysis supplementation regimen.

RDM53-rxlist-solriamfetol-sunosi-13ad0b1cfa-C1 · Source locator: Dosage: renal impairment, moderate, severe and ESRD paragraphs.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/sunosi-drug/
Retrieved
2026-09-09
Renal-function method
eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
bbd50ba554271a6fbd4dc0f5bba296f1e9259f2886c41ed3f485ba86d49e20f5

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/sunosi-drug/
Source retrieval
2026-09-09. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
71087033254d8e393ed74b3097ae21e779f692cb5575f36c8775a3bce780c950
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report